Featured Research

from universities, journals, and other organizations

Inhibiting macrophage MerTK signaling creates an innate immune response against cancer

Date:
July 8, 2013
Source:
University of North Carolina Health Care
Summary:
New evidence shows that MerTK macrophage action in the microenvironment that surrounds cancer cells blunts the immune response, allowing the tumor cell to grow and metastasize.

The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties -- clearing cells that die and healing damaged tissue.

New evidence by a University of North Carolina-led team published online on July 8 by the Journal of Clinical Investigation shows that MerTK macrophage action in the microenvironment that surrounds cancer cells blunts the immune response, allowing the tumor cell to grow and metastasize. The study, led by senior author Shelley Earp, MD, director of the UNC Lineberger Comprehensive Cancer Center, used mouse models bred without the gene for MerTK. Their work determined that MerTK absence increased the anti-tumor response and slowed the growth and spread of model breast, colon and skin cancers.

Several new drugs have recently been approved that effectively stimulate anti-tumor immunity. The evidence from the UNC researchers indicates that inhibiting MerTK in combination with these existing therapies may offer another avenue by which to activate the immune system in the fight against cancer.

Under normal circumstances, macrophages rid the body of normal debris while MerTK signaling evokes a wound healing, tissue repair response. With infection, the innate immune system, led by the macrophage, helps create an "angry" response aimed at eliminating foreign material.

UNC researchers theorized that, in the case of cancer cells derived from the cells of the body, MerTK action in the microenvironment surrounding the tumor cells might suppress the anti-tumor response and keep the immune system's T lymphovcytes from becoming active and killing tumor cells.

"In the first years of everyone's life, the immune system is 'educated' to tell the difference between 'self' and a foreign invader. Since tumor cells are part of our selves the immune system, unfortunately, becomes tolerant and fails to reject the tumor," said Dr. Earp.

Using model tumors, the research team examined the response of breast, skin and colon cancers growing in a mouse that lacked MerTK. They discovered that the tumors showed slower growth and a lower propensity to metastasize to other parts of the body. In the normal mouse, the MerTK macrophage signals were those of the wound healing type; whereas in the absence of MerTK, the entire immune system was activated, promoting inflammation.

"Our work strongly indicates that if you could inhibit MerTK signaling in the tumor bed, you could trigger a more active immune system leading to a stronger T-cell killing response against the tumor," said Dr. Earp.

While utilizing the immune system in the fight against cancer has been a goal of researchers for decades, the last four years have seen the development and approval of several drugs -- including the monoclonal antibodies Ipilimumab and Tremelimumab -- that prolong the anti-tumor T-cell response, resulting in clinical benefit particularly in melanoma. In some patients, these therapies have shown the ability not only to destroy cancer cells, but also to prevent the relapses that plague chemotherapy and even newer targeted agents.

The UNC Lineberger team is collaborating with the UNC Chemical Biology and Drug Discovery Center to discover, develop and test oral drugs that inhibit MerTK activity: compounds are currently being tested in animal models.

"We hope to create a new, more MerTK selective tool with which to stimulate the initial tumor response and combine this strategy with the existing drugs that extend the immune response. If we can initiate a stronger response and sustain that activity we may be more effective in treating metastatic cancer," said Dr Earp. "Tumor cells can move throughout the body thwarting some of our best therapeutic interventions. The immune system is mobile and may be able to help eliminate tumor cells even at distant sites."

The work was supported by The Breast Cancer Research Foundation and the UNC Breast Cancer SPORE. Team members included Rebecca Cook, PhD , now at Vanderbilt and Doug Graham, MD, PhD a former UNC School of Medicine graduate who now leads Pediatric Oncology research at the University of Colorado School of Medicine.


Story Source:

The above story is based on materials provided by University of North Carolina Health Care. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jennifer Schlegel, Maria J. Sambade, Susan Sather, Stergios J. Moschos, Aik-Choon Tan, Amanda Winges, Deborah DeRyckere, Craig C. Carson, Dimitri G. Trembath, John J. Tentler, S. Gail Eckhardt, Pei-Fen Kuan, Ronald L. Hamilton, Lyn M. Duncan, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Bentley R. Midkiff, Jing Liu, Weihe Zhang, Chao Yang, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Janiel M. Shields, Douglas K. Graham. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013; 123 (5): 2257 DOI: 10.1172/JCI67816

Cite This Page:

University of North Carolina Health Care. "Inhibiting macrophage MerTK signaling creates an innate immune response against cancer." ScienceDaily. ScienceDaily, 8 July 2013. <www.sciencedaily.com/releases/2013/07/130708143326.htm>.
University of North Carolina Health Care. (2013, July 8). Inhibiting macrophage MerTK signaling creates an innate immune response against cancer. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2013/07/130708143326.htm
University of North Carolina Health Care. "Inhibiting macrophage MerTK signaling creates an innate immune response against cancer." ScienceDaily. www.sciencedaily.com/releases/2013/07/130708143326.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins